@article{af320270ff3611ddb219000ea68e967b,
title = "Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response",
abstract = "BACKGROUND: A method has been developed to estimate a fitness landscape experienced by HIV-1 under treatment selective pressure as a function of the genotypic sequence thereby also estimating the genetic barrier to resistance. METHODS: We evaluated the performance of two estimated fitness landscapes (nelfinavir [NFV] and zidovudine [AZT] plus lamivudine [3TC]) to predict week 12 viral load (VL) change for 176 treatment change episodes (TCEs) and probability of week 48 virological failure for 90 TCEs, in treatment experienced patients starting these drugs in combination. RESULTS: A higher genetic barrier for AZT plus 3TC, (quantified per additional mutation required to develop resistance against these drugs) was associated with a 0.54 (95% confidence interval [CI] 0.30-0.77) larger log10 VL reduction at 12 weeks (P ",
author = "Koen Deforche and Alessandro Cozzi-Lepri and Kristof Theys and Bonaventura Clotet and Camacho, {Ricardo J} and J Kjaer and {Van Laethem}, Kristel and Andrew Phillips and Yves Moreau and Jens Lundgren and Anne-Mieke Vandamme and {Eurosida Study Group}",
note = "Keywords: Adult; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Models, Biological; Mutation; Nelfinavir; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Failure; Viral Load; Zidovudine",
year = "2008",
language = "English",
volume = "13",
pages = "399--407",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press",
number = "3",
}